Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Grows By 314.4%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 11,113 shares, a growth of 314.4% from the April 30th total of 2,682 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 14,125 shares, the short-interest ratio is presently 0.8 days.

Santen Pharmaceutical Stock Up 2.7%

SNPHY opened at $12.03 on Friday. Santen Pharmaceutical has a 12 month low of $9.22 and a 12 month high of $12.68. The company has a fifty day simple moving average of $11.25 and a 200 day simple moving average of $10.86. The stock has a market cap of $3.88 billion and a P/E ratio of 0.10.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, Santen Pharmaceutical has a consensus rating of “Hold”.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.